1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Celiac Research Partnership Builds Takeda’s GI Interests

 
• By Ian Haydock

Takeda continues to expand its interests in the gastrointestinal area through a joint research and development agreement with a small US venture for novel nanoparticle immune modulating therapies for celiac disease.

Takeda Pharmaceutical Co. Ltd. has already said that it sees gastroenterology and gastrointestinal therapies as core interests for its commercial and research portfolio, and the top Japanese pharma firm's latest collaboration bears out this focus.

Takeda has just signed a partnership with the privately held venture Cour Pharmaceutical Development Company to research and develop Cour's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly’s Orforglipron Makes Strong Showing In Diabetic Obesity Population

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.

Ascletis Confident Oral GLP-1 Challenger Can Best Lilly In Phase II

 
• By Andrew McConaghie

The China-headquartered company expects Phase II results from ASC30 later this year to outperform orforglipron and spark lots of big pharma interest.

OneSource CEO On Next-Gen GLP-1 Innovator Talks, Xbrane And Viatris Partnering

 
• By Vibha Ravi

OneSource Specialty CEO Neeraj Sharma discusses with Scrip exploratory talks with next-gen GLP-1 innovators, prospects for semaglutide generics and investment in Swedish firm Xbrane, among other topics.

Rhythm Gets US Decision Date For Hypothalamic Obesity Treatment

 
• By Andrew McConaghie

Already approved in two rare obesity conditions, Rhythm’s Imcivree looks on course to gain acquired hypothalamic obesity approval and reach blockbuster status.

More from Therapy Areas

GSK India Oncology Second Innings: Can Jemperli, Zejula Set The Pace?

 
• By Anju Ghangurde

GSK recommits to oncology in India with the debut of Jemperli and Zejula, backed by a tiered pricing approach, patient support program and efforts to address unmet needs in the biomarker ecosystem. Can it widen treatment access materially?

US FDA Suspends Valneva’s Ixchiq Based On Four New Serious AE Reports

 
• By Sue Sutter

After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.

AbbVie Buys Phase II MDD Candidate From Gilgamesh, But Not The Company

 
• By Joseph Haas

Partnered since May 2024, AbbVie and Gilgamesh agreed on a deal in which AbbVie will buy bretisilocin for up to $1.2bn, while Gilgamesh will spin out its remaining pipeline.